Product Images Truxima
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 5 images provide visual information about the product associated with Truxima NDC 63459-103 by Cephalon, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
image description - figure 1
PRINCIPAL DISPLAY PANEL - 100mg Vial Carton - figure 2
This is a chart that displays the percentage of ACR 20 responders over time for two groups of patients: one treated with placebo (n=201) and the other treated with Rituximab 2x1000mg (n=298). The chart shows that after 20 weeks, 100% of the patients in the Rituximab group were ACR 20 responders, while only 20% of the patients in the placebo group achieved the same response. The chart also shows that at 10 weeks, the percentage of responders was lower in both groups.*
PRINCIPAL DISPLAY PANEL - 500 mg Vial Carton - figure 3
figure 4
Truxima is a medication that comes in the form of an injection for intravenous use after dilution, contained in a single-dose vial. The medication contains rituximab-abbs, with a strength of 10 mg/mL. It is important for the pharmacist to provide the enclosed medication guide to the patient. No additional information is available.*
figure 5
Truxima is an intravenous medication containing rituximab-abbs used in the treatment of certain medical conditions. It comes in a single-dose vial with 500mg/50mL strength and should only be administered after dilution. Any unused portion should be discarded. Pharmacists are advised to provide the enclosed medication guide to the patient. This medication requires a prescription.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.